The European Commission has granted lenalidomide [Revlimid; Celgene Corporation] Orphan Medicinal Product Designation

2007 ◽  
Vol &NA; (1617) ◽  
pp. 18
Author(s):  
&NA;
2010 ◽  
Vol 61 (3) ◽  
pp. 311-322
Author(s):  
Adrijana Martinac ◽  
Siniša Tomić ◽  
Mirna Šimičić

New European Commission Regulation on Variations to the Terms of Marketing Authorisation for Medicinal Products and its Impact on Croatian LegislationVariations introduced to medicinal product documentation must not affect the quality, efficacy, and safety of the product. Croatian Medicinal Products Act and accompanying ordinances are largely aligned with the EU regulations. The EU has now tried to simplify the issue of variations with a new Regulation, creating differences in the definition of and approach to resolving certain types of variations between Croatia and the EU. These differences could hinder the approval procedure for variations in Croatia, particularly for medicines already approved in the EU. Amending the Croatian Ordinance on medicines already authorised in the EU would be one way of maintaining the efficiency of the Croatian regulatory system.


2013 ◽  
Vol 60 (Supplementum-VIII) ◽  
pp. 26-31 ◽  
Author(s):  
T. Foltánová ◽  
M. Mazág

Medical and scientific knowledge about rare diseases is minimal or lacking, thus making research difficulties for pharmaceutical industry. Orphan drugs in EU are under supervision of European Commission, European medical agency (EMA) and Committee for orphan medicinal products (COMP). The presentation provides a brief review of all supportive incentives in the field of orphan medicinal products as: the European orphan medicinal product (OMP) regulation, Guideline on Clinical Trials in Small Populations and Commission Regulation (EC) No 2049/2005 / support of small and medium enterprises (SMEs). It also introduces the concept of Clinical added value of orphan medicinal products, as one of the key instruments to increase the availability of orphan medicinal products in the member states. Separately it stresses the necessity of Health technology assessment implementation in whole process of orphan medicinal product development as well as the implementation of the Europlan indicators into the Slovak National plan


2020 ◽  
Vol 25 (2) ◽  
pp. 274-291 ◽  
Author(s):  
Maria E. Sheean ◽  
Eva Malikova ◽  
Dinah Duarte ◽  
Giuseppe Capovilla ◽  
Laura Fregonese ◽  
...  

2020 ◽  
Vol 13 (12) ◽  
pp. 425
Author(s):  
Anna Maria Piras ◽  
Ylenia Zambito ◽  
Maurizio Lugli ◽  
Baldassare Ferro ◽  
Paolo Roncucci ◽  
...  

The SARS-CoV-2 infection is associated with pulmonary coagulopathy, which determines the deposition of fibrin in the air spaces and lung parenchyma. The resulting lung lesions compromise patient pulmonary function and increase mortality, or end in permanent lung damage for those who have recovered from the COVID-19 disease. Therefore, local pulmonary fibrinolysis can be efficacious in degrading pre-existing fibrin clots and reducing the conversion of lung lesions into lasting scars. Plasminogen is considered a key player in fibrinolysis processes, and in view of a bench-to-bedside translation, we focused on the aerosolization of an orphan medicinal product (OMP) for ligneous conjunctivitis: human plasminogen (PLG-OMP) eye drops. As such, the sterile and preservative-free solution guarantees the pharmaceutical quality of GMP production and meets the Ph. Eur. requirements of liquid preparations for nebulization. PLG-OMP aerosolization was evaluated both from technological and stability viewpoints, after being submitted to either jet or ultrasonic nebulization. Jet nebulization resulted in a more efficient delivery of an aerosol suitable for pulmonary deposition. The biochemical investigation highlighted substantial protein integrity maintenance with the percentage of native plasminogen band > 90%, in accordance with the quality specifications of PLG-OMP. In a coherent way, the specific activity of plasminogen is maintained within the range 4.8–5.6 IU/mg (PLG-OMP pre-nebulization: 5.0 IU/mg). This is the first study that focuses on the technological and biochemical aspects of aerosolized plasminogen, which could affect both treatment efficacy and clinical dosage delivery. Increasing evidence for the need of local fibrinolytic therapy could merge with the availability of PLG-OMP as an easy handling solution, readily aerosolizable for a fast translation into an extended clinical efficacy assessment in COVID-19 patients.


2018 ◽  
Vol 23 (1) ◽  
pp. 26-48 ◽  
Author(s):  
Maria E. Sheean ◽  
Violeta Stoyanova-Beninska ◽  
Giuseppe Capovilla ◽  
Dinah Duarte ◽  
Matthias P. Hofer ◽  
...  

2018 ◽  
Vol 23 (3) ◽  
pp. 681-686 ◽  
Author(s):  
Stelios Tsigkos ◽  
Matthias Philipp Hofer ◽  
Maria Elzbieta Sheean ◽  
Segundo Mariz ◽  
Kristina Larsson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document